Jeroen B Van de Kamer
Overview
Explore the profile of Jeroen B Van de Kamer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
330
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pluim J, Pluim J, Van de Kamer J, van de Kamer J, Heeling E, Heeling E, et al.
Phys Med Biol
. 2025 Jan;
70(3.
PMID: 39813808
The treatment of breast cancer during pregnancy requires careful consideration of consequences for both maternal and fetal health. In non-pregnant patients, the use of radioactive iodine-125 (I)-seeds is standard practice...
2.
de Leeuw A, Giralt J, Tao Y, Benavente S, Nguyen T, Hoebers F, et al.
Radiother Oncol
. 2024 Nov;
202:110612.
PMID: 39522824
Purpose: To report on quality assurance (QA) and protocol adherence (PA) in a multicentre phase III trial for head and neck cancer, evaluate patterns of protocol deviations and investigate the...
3.
Al-Mamgani A, Kessels R, Gouw Z, Navran A, Mohan V, Van de Kamer J, et al.
Clin Transl Radiat Oncol
. 2023 Sep;
43:100676.
PMID: 37753461
Purpose: To report on the late toxicity and local control (LC) of head and neck cancer patients treated with adaptive FDG-PET/CT response-guided radiotherapy (ADMIRE) with dose escalation (NCT03376386). Materials And...
4.
Heeling E, Van de Kamer J, Methorst M, Bruining A, van de Meent M, Vrancken Peeters M, et al.
Cancers (Basel)
. 2023 Jun;
15(12).
PMID: 37370839
Introduction: Some aspects of the treatment protocol for breast cancer during pregnancy (PrBC) have not been thoroughly studied. This study provides clarity regarding the safety of the use of I-seeds...
5.
McDonald F, Belka C, Hurkmans C, Jereczek-Fossa B, Poortmans P, Van de Kamer J, et al.
Radiother Oncol
. 2023 May;
185:109724.
PMID: 37244357
No abstract available.
6.
Mohan V, Bruin N, Steenbakkers R, Noordzij W, Terhaard C, de Keizer B, et al.
Radiother Oncol
. 2022 Nov;
177:164-171.
PMID: 36368471
Background And Purpose: Xerostomia remains a common side effect of radiotherapy (RT) for patients with head and neck (H&N) cancer despite advancements in treatment planning and delivery. Secretory salivary gland...
7.
Langendijk J, Hoebers F, de Jong M, Doornaert P, Terhaard C, Steenbakkers R, et al.
Int J Part Ther
. 2021 Jul;
8(1):354-365.
PMID: 34285961
In the Netherlands, the model-based approach is used to identify patients with head and neck cancer who may benefit most from proton therapy in terms of prevention of late radiation-induced...
8.
La Fontaine M, Bruin N, van Kranen S, Knegjens J, Van de Kamer J, Vogel W, et al.
Radiother Oncol
. 2021 Apr;
160:107-114.
PMID: 33872642
Purpose: To test if the relative change in FDG-PET SUV over the course of treatment was associated with disease progression and overall survival. Additionally, the prognostic values of other first-order...
9.
Voncken F, Vegt E, van Sandick J, van Dieren J, Grootscholten C, Bartels-Rutten A, et al.
Strahlenther Onkol
. 2021 Apr;
197(9):791-801.
PMID: 33825916
Purpose: Respiratory-induced motion of oesophageal tumours and lymph nodes can influence positron-emission tomography/computed tomography (PET/CT). The aim was to compare standard three-dimensional (3D) and motion-compensated PET/CT regarding standardized uptake value...
10.
Vieira B, Demirtas D, Van de Kamer J, Hans E, Jongste W, van Harten W
PLoS One
. 2021 Feb;
16(2):e0247428.
PMID: 33606831
Background: Every week, radiotherapy centers face the complex task of scheduling hundreds of treatment sessions amongst the available linear accelerators. With the increase in cancer patient numbers, manually creating a...